SAG
AUPH icon

Spotlight Asset Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Spotlight Asset Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$428 Hold
75
– – ﹤0.01% 255
2024
Q1 		$376 Hold
75
– – ﹤0.01% 251
2023
Q4 		$583 Hold
75
– – ﹤0.01% 241
2023
Q3 		$583 Hold
75
– – ﹤0.01% 241
2023
Q2 		$726 Buy
+75
New +$778 ﹤0.01% 241

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Spotlight Asset Group's AUPH Position: Q2 2024 in Review

Spotlight Asset Group held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2024 at 75 shares worth $428. The position accounts for ﹤0.01% of the portfolio, ranked #255.

Spotlight Asset Group first reported a position in AUPH in Q2 2023 and has held it in 5 quarters since. The position peaked at $726 in Q2 2023. 171 funds tracked by Wall St. Rank hold AUPH as of Q2 2024.

  • Spotlight Asset Group held 75 shares of Aurinia Pharmaceuticals worth $428 as of Q2 2024.
  • Spotlight Asset Group left its Aurinia Pharmaceuticals share count unchanged in Q2 2024.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Spotlight Asset Group's portfolio in Q2 2024, its #255 holding.
  • Spotlight Asset Group first reported a position in Aurinia Pharmaceuticals in Q2 2023 and has held it in 5 quarters since.
  • Spotlight Asset Group's Aurinia Pharmaceuticals position peaked at $726 in Q2 2023.
  • 171 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2024.

Based on Spotlight Asset Group's 13F filing for Q2 2024, filed 24 Jul 2024.